Patient time requirements for anticoagulation therapy with warfarin
- PMID: 19773584
- PMCID: PMC4181607
- DOI: 10.1177/0272989X09343960
Patient time requirements for anticoagulation therapy with warfarin
Abstract
Background: Most patients receiving warfarin are managed in outpatient office settings or anticoagulation clinics that require frequent visits for monitoring.
Objective: To measure the amount and value of time required of patients for chronic anticoagulation therapy with warfarin.
Design: /Participants. Prospective observation of a cohort of adult patients treated at a university-based anticoagulation program. Measurements. Participants completed a questionnaire and a prospective diary of the time required for 1 visit to the anticoagulation clinic, including travel, waiting, and the clinic visit. The authors reviewed subjects' medical records to obtain additional information, including the frequency of visits to the anticoagulation clinic. They used the human capital method to estimate the value of time.
Results: Eighty-five subjects completed the study. The mean (median) total time per visit was 147 minutes (123). Subjects averaged 15 visits per year (14) and spent 39.0 hours (29.3) per year on their visits. Other anticoagulation-related activities, such as communication with providers, pharmacy trips, and extra time preparing food, added an average of 52.7 hours (19.0) per year. The mean annual value of patient time spent traveling, waiting, and attending anticoagulation visits was $707 (median $591). The mean annual value when also including other anticoagulation-related activities was $1799 (median $1132).
Conclusions: The time required of patients for anticoagulation visits was considerable, averaging approximately 2.5 hours per visit and almost 40 hours per year.
Methods: for reducing patient time requirements, such as home-based testing, could reduce costs for patients, employers, and companions.
Similar articles
-
Modeling patients' time, travel, and monitoring costs in anticoagulation management: societal savings achievable with the shift from warfarin to direct oral anticoagulants.BMC Health Serv Res. 2019 Nov 27;19(1):901. doi: 10.1186/s12913-019-4711-z. BMC Health Serv Res. 2019. PMID: 31775847 Free PMC article.
-
A multinational investigation of time and traveling costs in attending anticoagulation clinics.Value Health. 2008 Mar-Apr;11(2):207-12. doi: 10.1111/j.1524-4733.2007.00253.x. Value Health. 2008. PMID: 18380632 Clinical Trial.
-
Time-driven activity-based cost analysis for outpatient anticoagulation therapy: direct costs in a primary care setting with optimal performance.J Med Econ. 2019 May;22(5):471-477. doi: 10.1080/13696998.2019.1582058. Epub 2019 Mar 4. J Med Econ. 2019. PMID: 30744455
-
The economics of anticoagulation: what are the issues?Am J Manag Care. 2004 Oct;10(10 Suppl):S292-6. Am J Manag Care. 2004. PMID: 15605699 Review. No abstract available.
-
Clinical effectiveness and cost-effectiveness of different models of managing long-term oral anticoagulation therapy: a systematic review and economic modelling.Health Technol Assess. 2007 Oct;11(38):iii-iv, ix-66. doi: 10.3310/hta11380. Health Technol Assess. 2007. PMID: 17903392 Review.
Cited by
-
Low persistence to rivaroxaban or warfarin among patients with new venous thromboembolism at a safety net academic medical center.J Thromb Thrombolysis. 2020 Feb;49(2):287-293. doi: 10.1007/s11239-019-01959-x. J Thromb Thrombolysis. 2020. PMID: 31598931
-
Efficacy and Safety Outcomes for Patients Taking Warfarin Who Were Switched From Face-to-Face to Telephone Anticoagulation Clinic.Fed Pract. 2016 Jul;33(7):16-20. Fed Pract. 2016. PMID: 30766187 Free PMC article.
-
Prothrombin Complex Concentrate for Warfarin-Associated Intracranial Bleeding in Neurosurgical Patients: A Single-Center Experience.Medicina (Kaunas). 2018 Apr 25;54(2):22. doi: 10.3390/medicina54020022. Medicina (Kaunas). 2018. PMID: 30344253 Free PMC article.
-
Implementation and Quality Improvement of a Screening and Counseling Program for Unhealthy Alcohol Use in an Academic General Internal Medicine Practice.J Healthc Qual. 2017 Jan/Feb;39(1):15-27. doi: 10.1097/JHQ.0000000000000069. J Healthc Qual. 2017. PMID: 28045764 Free PMC article.
-
Cost-Effectiveness of Dabigatran (150 mg Twice Daily) and Warfarin in Patients ≥ 65 Years With Nonvalvular Atrial Fibrillation.Am J Cardiol. 2016 Jan 1;117(1):54-60. doi: 10.1016/j.amjcard.2015.09.048. Epub 2015 Oct 19. Am J Cardiol. 2016. PMID: 26552509 Free PMC article.
References
-
- AHRQ announces guide to help patients on Coumadin1/warfarin therapy. Available from: http://www.ahrq.gov/research/jul08/0708RA1.htm.
-
- Gold MR, Siegel JE, Russell LB, Weinstein MC, editors. Cost- Effectiveness in Health and Medicine. Oxford University Press; New York: 1996.
-
- Russell LB, Gold MR, Siegel JE, Daniels N, Weinstein MC. The role of cost-effectiveness analysis in health and medicine. Panel on Cost-Effectiveness in Health and Medicine. JAMA. 1996;276:1172–7. - PubMed
-
- Siegel JE, Weinstein MC, Russell LB, Gold MR. Recommendations for reporting cost-effectiveness analyses. Panel on Cost- Effectiveness in Health and Medicine. JAMA. 1996;276:1339–41. - PubMed
-
- Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the Panel on Cost-Effectiveness in Health and Medicine. JAMA. 1996;276:1253–8. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
